Further studies are essential for the development of GDF11‐ and other metabotrophins‐based systemic therapies for obesity and related cardio‐ and neurometabolic diseases, including Alzheimer's disease.1, 3. Here, GDF11 is linked to obesity due to melanocortin 4 receptor deficiency.